2013 Fiscal Year Final Research Report
Nanostructured Adjuvant for in situ Cancer Vaccination Used in Combined Physical-Immunotherapy
| Project/Area Number |
23700567
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Biomedical engineering/Biological material science
|
|---|
| Research Institution | National Institute of Advanced Industrial Science and Technology |
|---|
Principal Investigator |
WANG XIUPENG 独立行政法人産業技術総合研究所, ヒューマンライフテクノロジー研究部門, 主任研究員 (70598789)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
ITO Atsuo 独立行政法人 産業技術総合研究所, 研究グループ長 (30356480)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | アジュバント / 癌免疫 |
|---|
| Research Abstract |
Zn-, and Mg-containing tricalcium phosphates (TCP) and mesoporous silica (MS) with controllable pore size were selected as carriers for immune stimulating molecules (pathogen-associated molecular patterns-PAMPs). Using a PAMPs-containing supersaturated calcium phosphate solution, PAMPs-apatite composites were coprecipitated with TCP/MS to prepare the TCP/MS based adjuvants.
The TCP/MS based adjuvants showed in vitro and in vivo immunogenic activities. The TCP/MS based adjuvants mixed with liquid-nitrogen-treated tumor tissue markedly inhibited the in vivo development of rechallenged Lewis lung carcinoma cells. The cellular immune related cytokines (IL-2, IFNr, etc.) secretion in spleen and lymphocytes were improved after the TCP/MS based adjuvants injection. The TCP/MS based adjuvants contributed to eliciting cellular immune related antitumor immunity in vivo.
|
